

**Congress of the United States**  
**House of Representatives**  
Washington, DC 20515

September 9, 2025

Secretary Robert F. Kennedy, Junior  
Department of Health and Human Services  
200 Independence Avenue SW  
Washington, DC 20201

Dear Secretary Kennedy,

We, the undersigned members of Congress, write to express our concerns regarding the recently announced 340B Rebate Model Pilot Program. As the Department of Health and Human Services (HHS) notes, this change would “fundamentally shift how the 340B Program has operated for over 30 years.” Congress intended the 340B Program to enable the nation’s safety-net providers to stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services. An unchecked rebate model would severely undermine that purpose. We urge you to abandon the Rebate Model Pilot Program, or if the program must move forward, to proceed with the utmost caution and impose stronger guardrails to ensure the 340B program is not entirely dismantled.

As HHS is aware, last year, several multinational drug manufacturers—Bristol Myers Squibb (BMS), Eli Lilly, Johnson & Johnson (J&J), Novartis, and Sanofi—attempted to unilaterally impose rebate models on certain covered entities and drugs, despite a clear lack of statutory authority. We are grateful to the Health Resources & Services Administration (HRSA) for its swift and consistent enforcement efforts blocking manufacturers’ unlawful attempts to restructure the program without Secretarial approval. HRSA’s interpretation and enforcement against the rebate models were upheld by the U.S. District Court in the District of Columbia.<sup>1</sup>

We are concerned that HHS’s pilot program will severely damage community health centers, safety net hospitals, and other providers that rely on the 340B program to provide comprehensive, quality services to their patients and communities.

The rebate model pilot program will require all covered entities to purchase drugs on the CMS Medicare Drug Price Negotiation Selected Drug List at the wholesale acquisition cost – the highest sticker price that manufacturers offer, which is rarely actually paid by purchasers in the health care system. This will require 340B providers to float significant amounts of cash to drug

---

<sup>1</sup> “Eli Lilly and Company et al v. Robert F. Kennedy et al.” (2025)  
[https://sponsors.aha.org/rs/710-ZLL-651/images/2025-05-15\\_340B\\_Rebate\\_Models\\_Ruling](https://sponsors.aha.org/rs/710-ZLL-651/images/2025-05-15_340B_Rebate_Models_Ruling)

companies in hopes of a rebate being paid. Further, these drugs, despite their prices being reduced through price negotiation, are still some of the costliest drugs in the Medicare Part D program. If the entire 340B program moved to a rebate model, the average Disproportionate Share Hospital in the country would be forced to float an estimated \$72.2 million to manufacturers annually.<sup>2</sup>

This is a cost most 340B providers, many of whom are experiencing financial instability, simply cannot afford. 340B hospitals already have substantially lower—negative on average—operating margins compared to non-340B hospitals. And in 2023, nationally, nearly half of health centers had negative operating margins; overall net margins were 1.6 percent.<sup>3</sup> These changes threaten 340B providers' ability to provide care and to keep their doors open to serve low-income communities.

In addition, we are concerned that this rebate model will be used by manufacturers as a backdoor to recoup their own profits that may have been lost as a result of lowering prices through the Medicare Drug Price Negotiation Program (MDPNP). This was never Congress's intent in establishing the MDPNP. While we appreciate HRSA's attempts to place guardrails around this pilot program, these guardrails will not be sufficient to prevent aggressive tactics by manufacturers to deny claims and siphon money away from providers and their patients.

Finally, as we have affirmed on multiple occasions, we continue to believe that the rebate approach contravenes Congressional intent in establishing the 340B program and over three decades of precedent set by HRSA that distinguishes rebates and retroactive discounts from upfront 340B discounts.<sup>4</sup>

As such, we urge you to cancel the pilot program. However, if HHS chooses to continue with this pilot, we request answers to the following questions, no later than September 15, 2025:

1. HHS notes that this pilot would “fundamentally shift how the 340B Program has operated for over 30 years.” Yet the timeline for implementation of this pilot leaves little room for meaningful covered entity input, while mandating significant additional costs for those entities.

---

<sup>2</sup> Manufacturer 340B Rebate Models Threaten Safety-Net and Rural Hospitals and Would Harm Patients, 340B Health (2025).

[https://www.340bhealth.org/files/340B\\_Health\\_MANUFACTURER\\_340B\\_REBATE\\_MODELS\\_Report.pdf](https://www.340bhealth.org/files/340B_Health_MANUFACTURER_340B_REBATE_MODELS_Report.pdf)

<sup>3</sup> Federman, Sara; Bryan, Alexandra; Horstman, Celia; Lewis, Corinne. Community Health Centers Are Serving More Patients Than Ever, but Financial Challenges Loom Large, The Commonwealth Fund (2024).

<https://www.commonwealthfund.org/blog/2024/community-health-centers-are-serving-more-patients-ever-financial-challenges-loom-large>

<sup>4</sup> Final Notice on Entity Guidelines, 59 Fed. Reg. 25112; Notice on Initial Guidance, 58 Fed. Reg. 27291, 27292.

- a. What legal authority does HHS cite to support a 30-day public comment period, after which HHS is “under no obligation to respond or act on” any comments, in making this significant change?
  - b. What is HHS’s justification for imposing such significant changes on a rushed timeline, including only 30 days for public comment, one week to review public comments including input from 340B providers who have otherwise been uninvolved in the process, and four weeks to review manufacturers’ proposed plans?
2. How will the Information Technology (IT) platform be selected to ensure reduced administrative and logistic burden for covered entities, while avoiding any conflicts of interest? Will manufacturers be required to consider input from covered entities?
3. With regards to the determination of claims’ validity and issuance of rebates under the program:
  - a. What are HHS’s plans for ongoing audits and oversight to determine whether manufacturers are appropriately approving claims and issuing rebates in a timely manner?
  - b. If manufacturers do not pay rebates within 10 days of receiving covered entities’ submissions of data as required by the rebate model parameters, inappropriately deny entities’ claims, or otherwise use this pilot program to abuse the 340B Program, what enforcement tools will HHS use against noncompliant manufacturers? Will there be any special expedited procedures to allow covered entities to use the administrative dispute resolution (ADR) process to contest invalid manufacturer actions?
  - c. What additional criteria do HHS envision as permissible and impermissible for manufacturers to use as grounds to deny claims? For example, will HHS permit manufacturers to deny rebates by alleging that providers are not complying with the manufacturer’s unilaterally imposed restrictions on contract pharmacy?
4. The guidance states that “no additional administrative costs of running the rebate model shall be passed onto the covered entities.” How will HHS ensure this includes all administrative costs related to this rebate model pilot program, including labor costs and the costs of contesting denials? What enforcement mechanism will ensure that manufacturers pay all such costs in a timely manner?
5. The announcement notes that manufacturers can apply to participate for a “minimum of 1 year.”
  - a. What is the maximum amount of time HHS will permit manufacturers to run these rebate models?
  - b. Does HHS plan to re-evaluate the rebate model after one year to assess whether it will continue to permit manufacturers to remain in these rebate arrangements?
6. HHS states that it will evaluate “data and reports received from the participating manufacturers on the effectiveness of the model and covered entity and other stakeholder

feedback,” after which HHS may consider expanding the rebate model to other drugs purchased under the 340B program.

- a. Which performance measures will the agency use to measure effectiveness?
  - b. How will the ability of covered entities to provide care to underserved patients, as well as other feedback from covered entities, be weighed in the assessment of effectiveness?
  - c. Will the agency commit to make public the results of the assessments it conducts of the model’s effectiveness?
  - d. On what basis would the agency decide to increase the number of drugs subject to rebates by adding drugs with negotiated prices coming into effect in 2027 under the MDPNP?
  - e. On what basis would the agency determine to include drugs that are not under the MDPNP?
7. For many years and across several administrations, HHS has requested increased resources for implementation and oversight over the 340B Program. Yet this pilot program would significantly increase administrative burden for HHS staff, whose new responsibilities will include reviewing manufacturers’ applications and resolving any issues within 30 days from receipt, performing audits and ADR for any deviations from program guidelines, addressing issues raised by covered entities if there are issues with rebate delays and denials, and fielding any other administrative or logistical issues emerging through implementation of the rebate model. What is HHS’s plan to implement such a pilot program while maintaining regular oversight of the 340B program?

Sincerely,




---

Doris Matsui  
Member of Congress



---

Dusty Johnson  
Member of Congress



---

Debbie Dingell  
Member of Congress



---

Tracey Mann  
Member of Congress



---

Marie Gluesenkamp Perez  
Member of Congress



---

Mark Takano  
Member of Congress




---

John Rose  
Member of Congress



---

Joseph D. Morelle  
Member of Congress



---

Nydia M. Velázquez  
Member of Congress



---

Lloyd Doggett  
Member of Congress




---

Paul Tonko  
Member of Congress



---

Jim Tokuda  
Member of Congress




---

Stephen F. Lynch  
Member of Congress




---

Shontel M. Brown  
Member of Congress




---

Nikki Budzinski  
Member of Congress




---

William R. Keating  
Member of Congress



---

Yvette D. Clarke  
Member of Congress




---

Grace Meng  
Member of Congress




---

Becca Balint  
Member of Congress



---

Mark Pocan  
Member of Congress



---

Sharice L. Davids  
Member of Congress




---

Andre Carson  
Member of Congress




---

Lori Trahan  
Member of Congress



---

Angie Craig  
Member of Congress




---

Jan Schakowsky  
Member of Congress



---

Marc A. Veasey  
Member of Congress



---

Nikema Williams  
Member of Congress




---

Jim Costa  
Member of Congress




Ayanna Pressley  
Member of Congress




Gabe Vasquez  
Member of Congress



Ilhan Omar  
Member of Congress



Sean Casten  
Member of Congress



Haley M. Stevens  
Member of Congress



Dina Titus  
Member of Congress



Mike Thompson  
Member of Congress



Lateefah Simon  
Member of Congress



Juan Vargas  
Member of Congress



Betty McCollum  
Member of Congress



John Garamendi  
Member of Congress



Greg Casar  
Member of Congress



---

J. Luis Correa  
Member of Congress



---

Chellie Pingree  
Member of Congress



---

Emilia Strong Sykes  
Member of Congress




---

Sara Jacobs  
Member of Congress



---

Ed Case  
Member of Congress



---

Kelly Morrison  
Member of Congress



---

Steve Cohen  
Member of Congress



---

Henry C. "Hank" Johnson, Jr.  
Member of Congress



---

Chrissy Houlahan  
Member of Congress




---

Chris Pappas  
Member of Congress



---

Delia C. Ramirez  
Member of Congress



---

Adam Smith  
Member of Congress



---

David G. Valadao  
Member of Congress



---

Sam Graves  
Member of Congress



---

Dwight Evans  
Member of Congress



---

Rick Larsen  
Member of Congress




---

Julia Brownley  
Member of Congress



---

Val Hoyle  
Member of Congress



---

Jared Golden  
Member of Congress



---

Greg Landsman  
Member of Congress



---

Raja Krishnamoorthi  
Member of Congress



---

Valerie P. Foushee  
Member of Congress



---

Zoe Lofgren  
Member of Congress




---

Salud Carbajal  
Member of Congress



---

Rashida Tlaib  
Member of Congress



---

Andrea Salinas  
Member of Congress




---

Veronica Escobar  
Member of Congress



---

Ritchie Torres  
Member of Congress



---

Bennie G. Thompson  
Member of Congress




---

Emanuel Cleaver, II  
Member of Congress



---

Greg Stanton  
Member of Congress




---

Jack Bergman  
Member of Congress



---

Thomas R. Suozzi  
Member of Congress




---

Adriano Espaillat  
Member of Congress



---

Ro Khanna  
Member of Congress



---

Seth Magaziner  
Member of Congress



---

Kim Schrier, M.D.  
Member of Congress




---

Maxine Dexter  
Member of Congress



---

George Latimer  
Member of Congress



---

Sylvia R. Garcia  
Member of Congress



---

Derek T. Tran  
Member of Congress




---

Eleanor Holmes Norton  
Member of Congress



---

James P. McGovern  
Member of Congress




---

Jesús G. "Chuy" García  
Member of Congress



---

Don Bacon  
Member of Congress



---

Kathy Castor  
Member of Congress




---

Young Kim  
Member of Congress



---

Alexandria Ocasio-Cortez  
Member of Congress



---

Hillary J. Scholten  
Member of Congress




---

Patrick K. Ryan  
Member of Congress



---

Eric Swalwell  
Member of Congress



---

Mike Flood  
Member of Congress



---

Mike Quigley  
Member of Congress



---

Dan Goldman  
Member of Congress




---

Lois Frankel  
Member of Congress



---

Maggie Goodlander  
Member of Congress



---

Gilbert Ray Cisneros, Jr.  
Member of Congress




---

Debbie Wasserman Schultz  
Member of Congress




---

Lizzie Fletcher  
Member of Congress



---

Jerrold Nadler  
Member of Congress



Suzanne Bonamici  
Member of Congress




Lucy McBath  
Member of Congress



Mary Gay Scanlon  
Member of Congress



Shri Thanedar  
Member of Congress




Timothy M. Kennedy  
Member of Congress



Suzan K. DelBene  
Member of Congress



Pete Stauber  
Member of Congress



Judy Chu  
Member of Congress



Emily Randall  
Member of Congress




Rob Bresnahan, Jr.  
Member of Congress



Kimberlyn King-Hinds  
Member of Congress




Gwen S. Moore  
Member of Congress




---

Danny K. Davis  
Member of Congress




---

Gregory W. Meeks  
Member of Congress



---

Michael V. Lawler  
Member of Congress



---

Jonathan L. Jackson  
Member of Congress



---

Robert Garcia  
Member of Congress




---

Ami Bera, M.D.  
Member of Congress



---

Josh Harder  
Member of Congress




---

Sanford D. Bishop, Jr.  
Member of Congress



---

Terri A. Sewell  
Member of Congress



---

Shomari Figures  
Member of Congress



---

John W. Mannion  
Member of Congress



---

Eric Sorensen  
Member of Congress



---

Darren Soto  
Member of Congress



---

Jasmine Crockett  
Member of Congress




---

Frank J. Mrvan  
Member of Congress




---

Ted W. Lieu  
Member of Congress



---

Henry Cuellar  
Member of Congress



---

Kristen McDonald Rivet  
Member of Congress



---

Jimmy Panetta  
Member of Congress



---

Frederica S. Wilson  
Member of Congress



---

Troy A. Carter, Sr.  
Member of Congress



---

Joyce Beatty  
Member of Congress (OH-03)



---

Jefferson Van Drew  
Member of Congress



---

Diana DeGette  
Member of Congress



---

Jason Crow  
Member of Congress



---

Robin L. Kelly  
Member of Congress



---

Mark DeSaulnier  
Member of Congress




---

Maxine Waters  
Member of Congress



---

Josh Riley  
Member of Congress




---

Kweisi Mfume  
Member of Congress



---

Julie Johnson  
Member of Congress



---

Seth Moulton  
Member of Congress



---

Derek Schmidt  
Member of Congress




---

Joaquin Castro  
Member of Congress



---

Bill Foster  
Member of Congress



---

Sam T. Liccardo  
Member of Congress



---

Nick LaLota  
Member of Congress



---

Nancy Pelosi  
Member of Congress




---

Michael K. Simpson  
Member of Congress



---

Derrick Van Orden  
Member of Congress



---

Cleo Fields  
Member of Congress




---

Chris Deluzio  
Member of Congress



---

Pablo José Hernández  
Member of Congress



---

Joe Neguse  
Member of Congress



---

Gabe Amo  
Member of Congress



---

Bradley Scott Schneider  
Member of Congress



---

Susie Lee  
Member of Congress



---

Madeleine Dean  
Member of Congress



---

Pramila Jayapal  
Member of Congress



---

Mike Bost  
Member of Congress




---

Dan Meuser  
Member of Congress



---

Randy Feenstra  
Member of Congress



---

Adam Gray  
Member of Congress



---

Andrew R. Garbarino  
Member of Congress